• Welcome, Guest. Please login or register.
    April 25, 2019, 09:43:48 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:


Click to visit us on Facebook

If you have any problems registering or signing in, please send an email to: andy@thalpal.com
Please do not send questions about thalassemia to this address.


Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2018

55001 Posts in 5847 Topics by 6101 Members
Latest Member: btiproject

Forum Tip: 
You can change your member name in your profile, under "Account Related Settings," so you don't have to re-register to change it.
« previous next »
Pages: 1 Go Down Print
Author Topic: LentiGlobin G3ne Therapy Hope to have it soon  (Read 904 times)
New Member
Offline Offline

Posts: 5

« on: November 19, 2018, 11:35:49 AM »

bluebird bio visited the CAF office last week to discuss the development of LentiGlobin gene therapy for the treatment of transfusion-dependent beta thalassemia. Here are a few of their updates:

(1) bluebird bio recently filed a Marketing Authorization Application with the European Medicines Agency (EMA) to determine whether gene therapy might be approved for use in the European Union for the treatment of transfusion-dependent beta thalassemia. The length of time this review process may take is up to the EMA, but bluebird expects to hear an answer from them sometime in 2019.

(2) bluebird bio has not yet filed a New Drug Application (NDA) for LentiGlobin with the U.S. FDA. However, they are continuing to engage with the FDA. To date, the FDA has granted LentiGlobin both Orphan Drug status and Breakthrough Therapy designation for the treatment of transfusion-dependent thalassemia.

(3) bluebird bio is actively engaging with health technology assessment (HTA) bodies, payers, and other authorities in the U.S. and Europe to discuss models that recognize the value of gene therapy treatments and how to align payment with value over time. Their goal is to potentially create new pricing and reimbursement models that responsibly reflect the value that a one-time transformational treatment brings to patients, families, the healthcare system and society.

(4) bluebird bio will be providing an update on the latest findings from their clinical trials at the upcoming American Society of Hematology (ASH) meeting in early December.
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!